Company intelligence / Profile preview

Dilafor AB

Ownership: Private
Development stage: Other

Overview

Dilafor AB develops tafoxiparin, a proprietary heparan sulfate mimetic designed to improve cervical ripening and facilitate the onset of labor. Clinical studies have shown that tafoxiparin can significantly increase the rate of spontaneous onset of labor or achievement of a ripe cervix, with demonstrated safety in over 650 pregnant women. The drug aims to reduce maternal/fetal complications associated with induced or protracted labor. Recent extension studies have yielded positive results supporting continued development.

Therapeutic areas: Women's Health
Modalities: Small molecules (heparan sulfate mimetic)
Industry: Biotech

Drug pipeline

1 asset

tafoxiparin

Partnerships

Lee’s Pharmaceutical Holdings Limited/Lee’s Healthcare Industry Fund L.P.: License agreement for development/commercialization in China, Hong Kong, Macau, Taiwan.Opocrin SpA (API expertise partner/investor)

Beyond the preview

Go deeper on Dilafor AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dilafor AB.